Recommended Immunizations to Reduce Respiratory Morbidity and Mortality Among US Adults With Asthma, by Age.

Details

• Alternative Title:
  Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology, 2025, v. 134, no. 5: Recommended Immunizations to Reduce Respiratory Morbidity and Mortality Among US Adults With Asthma, by Age.
• Journal Article:
  Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
• Personal Author:
  Dowling, Tia C. ; Shah, Melisa M. ; Moulia, Danielle L. ; Hsu, Joy
• Description:
  Respiratory infections, including some that are preventable by vaccination, can trigger asthma attacks. The figure is a summary of some vaccines recommended for US adults with asthma. These recommendations largely parallel recommendations for adults without asthma. For example:
  
  • A 2024-2025 COVID-19 vaccination is recommended for all adults to protect against severe COVID-19-associated illness and death.1,2 A second dose of 2024-2025 COVID-19 vaccine is recommended for people 65 years and older and people with moderate or severe immunocompromise.3 Footnote 2 (Figure) has more information on COVID-19 vaccination.
  
  • To protect against pertussis, all adults should receive one dose of Tdap vaccine if they did not receive Tdap on or after the age of 10 years. A Td or Tdap booster every 10 years is recommended for all adults to prevent tetanus and diphtheria.1
  
  • Routine annual influenza vaccination is recommended for all persons aged ≥6 months who have no contraindications. All persons should receive an age-appropriate influenza vaccine (i.e., one approved for their age). The exception is that solid organ transplant recipients aged 18-64 years receiving immunosuppressive medication regimens may receive trivalent high-dose inactivated influenza vaccine (HD-IIV3) or trivalent adjuvanted inactivated influenza vaccine (aIIV3) as acceptable options, without a preference over other age-appropriate inactivated or recombinant influenza vaccines.1,4 Trivalent high-dose inactivated influenza vaccine (HD-IIV3), trivalent recombinant influenza vaccine (RIV3), and trivalent adjuvanted inactivated influenza vaccine (aIIV3) are preferentially recommended for persons aged ≥65 years.
• Content Notes:
  Author manuscript
• Subjects:
  • Humans
  • Adult
  • COVID-19
  • COVID-19 Vaccines
  • Diphtheria
  • Influenza Vaccines
  • Influenza, Human
  • Tetanus
  • Whooping Cough
  • Organ Transplantation
  More +
• Source:
  Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology, 2025, v. 134, no. 5
• DOI:
  https://doi.org/10.1016/j.anai.2025.01.019
• ISSN:
  1081-1206 ; 1534-4436
• Pubmed ID:
  40345715
• Pubmed Central ID:
  PMC12356084
• Document Type:
  Text
• Funding:
  CC999999/ImCDC/Intramural CDC HHSUnited States/
• Genre:
  Journal Article
• Pages in Document:
  535-538 (6 pdf pages)
• Volume:
  134
• Issue:
  5
• Download URL:
  https://stacks.cdc.gov/view/cdc/261423/cdc_261423_DS1.pdf
• File Type:
  [PDF - 309.68 KB]
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha-512:8d4df803fdd7a9d8970cbe20e0b09791a4baf145af8ca3e476fc41953c2272465f9599956bee54d94ac51b6c0a2622870325305928cde006df50daff322a0255